Turning Down the Volume on Opioid Cravings? What Early GLP-1 Studies Actually Found

Headlines love a tidy comparison. Over the past two years, medicines like semaglutide and liraglutide have been described as “quieting food noise,” and some writers have stretched the image further, suggesting these drugs might quiet the noise of addiction too. It is a catchy simile. Cravings, after all, can feel like a radio stuck on one station, loud and impossible to tune out.

But a simile is only as good as the evidence underneath it. When it comes to opioids, the research is still young, and the details matter. Readers following the early human trials of GLP 1 for addiction deserve a clear account of what was measured, how many people took part, and what remains unknown. That clarity is just as important for families weighing proven care, including medication for opioid use disorder and structured residential programs, against options that are still being tested.

Here is what the studies so far actually show, and why the “volume knob” comparison should be used carefully.

The Study That Started the Conversation

In February 2024, Penn State researcher Patricia “Sue” Grigson presented results at the annual meeting of the American Association for the Advancement of Science from what was described as the first randomized controlled trial testing a GLP-1 medication for opioid use disorder. The study was funded by the National Institute on Drug Abuse and Novo Nordisk, the manufacturer of liraglutide.

Twenty people receiving residential treatment for opioid use disorder were given daily injections of either placebo or escalating doses of liraglutide over three weeks. Participants rated their cravings several times a day through phone notifications. As reported by STAT News, those on liraglutide experienced about a 40% reduction in opioid cravings, with effects seen even at the lowest dose.

The Fine Print That Matters

The same reports were clear about the limits. Only nine of the 20 participants completed the three weeks. Gastrointestinal side effects, which are well known with this drug class, were twice as common in the liraglutide group and drove much of the dropout. The study measured cravings, not long-term abstinence or overdose. The researchers themselves said the results needed confirmation in larger trials.

What Large Health Records Suggest

A second line of evidence comes from real-world data. In October 2024, a team led by Fares Qeadan of Loyola University Chicago published a retrospective study in the journal Addiction. They analyzed health records from more than 500,000 people with a history of opioid use disorder and more than 817,000 with a history of alcohol use disorder.

People with opioid use disorder who had GLP-1 or related prescriptions showed about a 40% lower rate of opioid overdose than those without such prescriptions. Among people with alcohol use disorder, the rate of alcohol intoxication was about 50% lower.

These are striking associations. However, a retrospective study cannot prove that the medication caused the difference. People who receive these prescriptions may differ in many ways, including access to regular medical care, which could also influence outcomes.

Why the “Volume Knob” Simile Can Mislead

Comparisons are helpful when they clarify and harmful when they overpromise. Before repeating the volume knob image, it helps to keep a few cautions in mind.

Cravings are not the whole disorder. Opioid use disorder involves physical dependence, withdrawal, mental health factors, and environment. Reducing cravings in a short study does not mean the underlying condition has been treated. Analysts at GlobalData have noted that some experts question how well laboratory craving measures translate to the real world.
Small samples make big swings. With 20 participants and fewer than half finishing, a single person’s experience can shift the results noticeably. Larger trials are needed before the effect size can be trusted.
Side effects affect real-world use. If many people stop a medication because of nausea or other digestive problems, its practical benefit may be smaller than its laboratory effect. Tolerability is part of effectiveness.
Proven medications already exist. Buprenorphine, methadone, and naltrexone are FDA-approved for opioid use disorder. In the Penn State study, participants already taking buprenorphine who also received liraglutide were more likely to report zero cravings, which suggests researchers see GLP-1 drugs as a possible addition, not a replacement.
Association is not causation. The health records study is valuable for generating questions, but it cannot answer them on its own. Only well-designed randomized trials can show whether the medication itself is responsible.

A better simile might be a dimmer switch being tested in a single room. It may work, and early signs are encouraging, but nobody yet knows how it will perform across the whole house.

Where This Fits With Current Treatment

Federal data shows how much room there is to improve existing care. SAMHSA’s 2024 National Survey on Drug Use and Health found that only 17% of the 4.8 million people with a past-year opioid use disorder received medications for opioid use disorder. Closing that gap does not depend on new drugs. It depends on getting people connected to treatments that already work.

SAMHSA’s guidance on quality treatment recommends looking for programs that are state licensed, offer FDA-approved medications, use evidence-based therapies, involve families, and provide ongoing support. Any future role for GLP-1 drugs would most likely sit inside that kind of comprehensive plan, guided by physicians who can monitor side effects and interactions.

Reading the Next Headline Wisely

More research is underway. The Penn State team described a follow-up trial planned to last three months, measuring both cravings and abstinence, and including semaglutide. When results arrive, ask a few simple questions. How many people took part? How long did the study last? What exactly was measured? Who funded it?

Similes are wonderful tools for understanding. They just should not run ahead of the data. For now, the most accurate comparison may be the plainest one: promising, early, and not yet proven.

Frequently Asked Questions (FAQs)

1. Can GLP-1 medications treat opioid addiction?

Early research is promising but limited. A small three-week trial found reduced opioid cravings with liraglutide, and a large records study found lower overdose rates among people with GLP-1 prescriptions. Larger randomized trials are still needed.

2. What are the proven medications for opioid use disorder?

Buprenorphine, methadone, and naltrexone are FDA-approved for opioid use disorder. SAMHSA recommends that quality treatment programs offer access to these medications along with counseling and ongoing support.

3. Should someone start a GLP-1 drug on their own to reduce cravings?

No. These medications carry side effects and are not a substitute for established addiction care. Anyone curious about them should talk with a licensed physician who can review their full medical history.